G. Hackett

A. Heald, G. Hackett, M. Livingston, 2018, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes

R. Strange, G. Hackett, Peter W. Jones, 2017, World journal of diabetes.

Coronary Heart Disease, Diabetes, and Sexuality in Men.

D. Baldwin, K. McVary, G. Hackett, 2016, The journal of sexual medicine.

Sexual health and wellbeing

G. Hackett, 2017 .

The burden and extent of comorbid conditions in patients with erectile dysfunction

G. Hackett, Geoffrey Hackett, 2009, International journal of clinical practice.

New testosterone 2% gel using Ferring Advanced Skin Technology (FAST), for the treatment of testosterone deficiency in men, with a novel applicator

G. Hackett, A. Kalhan, Michael Kirby, 2020, Expert review of endocrinology & metabolism.

British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice.

G. Hackett, N. Ossei-Gerning, A. Muneer, 2017, The journal of sexual medicine.

Testosterone and the Heart

G. Hackett, M. Kirby, S. Ramachandran, 2019, European cardiology.

Erectile dysfunction and coronary artery disease prediction: evidence‐based guidance and consensus

F. Montorsi, R. Kloner, C. Vlachopoulos, 2010, International journal of clinical practice.

Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners

G. Hackett, I. Eardley, D. Ralph, 2007, BJU international.

Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): a randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naïve men with ED and their partners.

G. Hackett, J. Curram, D. Edwards, 2006, The journal of sexual medicine.

Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction

G. Hackett, I. Eardley, V. Gentile, 2004, BJU international.

Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30‐week randomized placebo‐controlled study

N. Cole, R. Strange, P. Jones, 2017, Andrology.

Can simvastatin improve erectile function and health‐related quality of life in men aged ≥40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971]

D. Trivedi, G. Hackett, Shehzad Ali, 2013, BJU international.

The clinical importance of testosterone in men with type 2 diabetes

G. Hackett, 2010 .

Biochemical hypogonadism in men with type 2 diabetes in primary care practice

N. Cole, G. Hackett, D. Kennedy, 2009 .

Patient Choice is Critical in Managing Erectile Dysfunction

G. Hackett, J. Heaton, R. Padley, 2002 .

Testosterone Deficiency, Cardiac Health, and Older Men

G. Hackett, A. Sinclair, M. Kirby, 2014, International journal of endocrinology.

Lessons learnt from the variation across 6741 family/general practices in England in the use of treatments for hypogonadism

A. Heald, G. Hackett, M. Whyte, 2021, Clinical endocrinology.

Low Testosterone on Hospital Admission with COVID-19 Infection Is Associated with Increased Mortality

G. Hackett, Aiden J. Plant, A. Hartland, 2022, Androgens: Clinical Research and Therapeutics.

Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME)

S. Arver, R. Quinton, A. Dobs, 2016, International journal of clinical practice.

Is late-onset hypogonadotropic hypogonadism a specific age-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden?

G. Hackett, A. Aversa, M. Maggi, 2016, Minerva endocrinologica.

Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis

T. Travison, E. Giltay, R. Quinton, 2022, The Lancet. Healthy longevity.

The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study)

N. Cole, G. Hackett, A. Saghir, 2014, International journal of clinical practice.

Testosterone Replacement Therapy and Mortality in Older Men

G. Hackett, 2016, Drug Safety.

Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study.

N. Cole, G. Hackett, D. Kennedy, 2014, The journal of sexual medicine.

Benefits of testosterone replacementHACKETT

G. Hackett, 2013 .

Testosterone and the heart

G. Hackett, 2012, International journal of clinical practice.

Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30‐week randomized placebo‐controlled study

N. Cole, R. Strange, G. Hackett, 2016, BJU international.

An update on the role of testosterone replacement therapy in the management of hypogonadism

G. Hackett, 2016, Therapeutic advances in urology.

Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.

N. Cole, G. Hackett, D. Kennedy, 2013, The journal of sexual medicine.

Review: Androgens, erectile dysfunction and cardiovascular risk in type 2 diabetes

G. Hackett, 2009 .

The 2018 Revision to the Process of Care Model for Management of Erectile Dysfunction.

W. Hellstrom, E. Jannini, G. Hackett, 2018, The journal of sexual medicine.

A shared care approach to the management of erectile dysfunction in the community

F. Montorsi, C. Stief, F. Debruyne, 2002, International Journal of Impotence Research.

Should PDE5Is be prescribed routinely for all men with newly diagnosed type 2 diabetes

G. Hackett, 2015 .

UK policy statements on testosterone deficiency

G. Hackett, A. Muneer, M. Kirby, 2017, International journal of clinical practice.

NHS services for erectile dysfunction: a case of orchestrated chaos?

G. Hackett, 2011 .

BSSM guidelines on testosterone deficiency: a summary

G. Hackett, M. Kirby, 2018 .

A New Perspective on the Nitrate–Phosphodiesterase Type 5 Inhibitor Interaction

R. Kloner, I. Goldstein, I. Osterloh, 2018, Journal of cardiovascular pharmacology and therapeutics.

Androgen receptor-reduced sensitivity is associated with increased mortality and poorer glycaemia in men with type 2 diabetes mellitus: a prospective cohort study

M. Rutter, R. Donn, M. Lunt, 2020, Cardiovascular endocrinology & metabolism.

The ability of men to assess their suitability to take a phosphodiesterase type 5 inhibitor: an assessment of the comprehension of patient information materials.

K. Coyne, T. Symonds, M. Margolis, 2010, The journal of sexual medicine.

Erectile dysfunction: is the NHS men's health friendly?

G. Hackett, M. Kirby, S. Ramachandran, 2020, Trends in Urology & Men's Health.

Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate

G. Hackett, W. Dinsmore, R. Oakes, 2007, Current medical research and opinion.

Further reassurance regarding PDE5 inhibitors

G. Hackett, 2007, International journal of clinical practice.

COVID-19, Type 2 Diabetes, and Hypogonadism: Lessons for Acute Management and Long-Term Prevention

G. Hackett, M. Kirby, 2020 .

What Do Patients Expect from Erectile Dysfunction Therapy

G. Hackett, 2002 .

A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.

Edward D. Kim, F. Montorsi, G. Hackett, 2012, The journal of sexual medicine.

Cardiac events and phosphodiesterase type 5 inhibitors – time to end the myth of impending doom?

G. Hackett, 2008, International journal of clinical practice.

Evidence based medicine inevitably increases testosterone prescribing

G. Jackson, G. Hackett, K. Wylie, 2012, BMJ : British Medical Journal.

Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).

R. Quinton, K. Kurth, F. Debruyne, 2017, Journal of Sexual Medicine.

International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation.

I. Goldstein, Kwangsung Park, W. Hellstrom, 2010, The journal of sexual medicine.

The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease.

R. Kloner, C. Vlachopoulos, I. Goldstein, 2012, Mayo Clinic proceedings.

Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study.

G. Hackett, R. Rosen, M. Warner, 2006, The journal of sexual medicine.

Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol‐delivery form of lidocaine‐prilocaine for treating premature ejaculation

G. Hackett, D. Goldmeier, W. Dinsmore, 2007, BJU international.

THREE‐YEAR UPDATE OF SILDENAFIL CITRATE (VIAGRA®) EFFICACY AND SAFETY

G. Hackett, M. Moskowitz, R. Sadovsky, 2001, International journal of clinical practice.

Summary of the recommendations on sexual dysfunctions in men.

John Dean, David Rowland, Mario Maggi, 2004, The journal of sexual medicine.

All men with vasculogenic erectile dysfunction require a cardiovascular workup.

R. Kloner, C. Vlachopoulos, I. Goldstein, 2014, The American journal of medicine.

The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician

R. Kloner, C. Vlachopoulos, I. Goldstein, 2013, International journal of clinical practice.

Testosterone supplementation and sexual function: a meta-analysis study.

A. Lenzi, A. Isidori, G. Hackett, 2014, The journal of sexual medicine.

Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education.

G. Hackett, 2005, Clinical cornerstone.

The pharmacist's role in improving the treatment of erectile dysfunction and its underlying causes.

Evelyn R. Hermes-DeSantis, R. Kloner, G. Hackett, 2019, Research in social & administrative pharmacy : RSAP.

Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome.

G. Hackett, 2019, Sexual medicine reviews.

Sex Hormone Binding Globulin: A Review of its Interactions With Testosterone and Age, and its Impact on Mortality in Men With Type 2 Diabetes.

R. Strange, G. Hackett, S. Ramachandran, 2019, Sexual medicine reviews.

Managing Clinical Heterogeneity: An Argument for Benefit-Based Action Limits

C. S. König, Mark Livingston, S Ramachandran, 2018 .

The Cost to the United Kingdom National Health Service of Managing Erectile Dysfunction

P. Scuffham, G. Hackett, E. Wilson, 2012, PharmacoEconomics.

Diagnosis and treatment of erectile dysfunction for reduction of cardiovascular risk.

R. Kloner, C. Vlachopoulos, I. Goldstein, 2013, The Journal of urology.

Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality

S. Anderson, M. Rutter, M. Woodward, 2014, Heart.

Testosterone replacement therapy and cardiovascular events

G. Hackett, 2014, BMJ : British Medical Journal.

Long-Term Testosterone Therapy in Type 2 Diabetes Is Associated with Decreasing Waist Circumference and Improving Erectile Function

N. Cole, R. Strange, G. Hackett, 2018, The world journal of men's health.

Long‐term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors

N. Cole, R. Strange, G. Hackett, 2018, BJU international.

Testosterone Therapy: An Assessment of the Clinical Consequences of Changes in Hematocrit and Blood Flow Characteristics.

R. Strange, G. Hackett, C. König, 2019, Sexual medicine reviews.

Erectile Dysfunction: Current Investigation and Management

G. Hackett, 2005, Journal of Family Planning and Reproductive Health Care.

Testosterone deficiency in men infected with COVID‐19

G. Hackett, M. Kirby, 2020, Trends - Urology & Men's Health.

A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction

G. Hackett, J. Dean, E. Curless, 1999, International Journal of Impotence Research.

Confusion still reigns in premature ejaculation management

G. Hackett, 2007, International journal of clinical practice.

Male hypogonadism: 14‐year prospective outcome in 550 men with type 2 diabetes

M. Rutter, R. Donn, B. Keevil, 2019, Endocrinology, diabetes & metabolism.

Quality of Life and Sexual Function Benefits Effects of Long-Term Testosterone Treatment: Longitudinal Results from the Registry of Hypogonadism (RHYME)

R. Quinton, K. Kurth, G. Hackett, 2017 .

Klinefelters Syndrome: Change in T-Scores with Testosterone, Bisphosphonate, and Vitamin D Treatment Over 6 Years

R. Strange, G. Hackett, C. König, 2021, Androgens: Clinical Research and Therapeutics.

The number of androgen receptor CAG repeats and mortality in men

D. Vanderschueren, A. Heald, G. Hackett, 2022, The aging male : the official journal of the International Society for the Study of the Aging Male.

The treatment rate of erectile dysfunction (ED) in younger men with type 2 diabetes is up to four times higher than the equivalent non‐diabetes population

S. Anderson, M. Lunt, A. Heald, 2020, International journal of clinical practice.

Cardiovascular and Cerebrovascular Safety of Testosterone Therapy.

A. Traish, G. Hackett, M. Miner, 2019, The American journal of medicine.

A practical guide to the assessment and management of testosterone deficiency in adult men

G. Hackett, M. Kirby, 2023, Trends in Urology & Men's Health.

PDE5 inhibitors in diabetic peripheral neuropathy

G. Hackett, 2006, International journal of clinical practice.

The increasing role of PDE5Is in men with diabetes and cardiovascular disease

G. Hackett, M. Kirby, 2023, Trends in Urology & Men's Health.

Is premature ejaculation all in the mind?

G. Hackett, I. Eardley, R. Kirby, 2005, BJU International.

Important lessons about testosterone therapy- weight loss vs. testosterone therapy for symptom resolution, classical vs. functional hypogonadism, and shortterm vs. lifelong testosterone therapy

G. Hackett, Monica Caliber, 2019, The aging male : the official journal of the International Society for the Study of the Aging Male.

Schedule 11 — impact on treating erectile dysfunction

G. Hackett, 2002 .

Services for erectile dysfunction in the UK – a 12‐month review of referrals to a west Midlands NHS clinic

G. Hackett, N. Cole, 2010, International journal of clinical practice.

Testosterone and the Heart

G. Hackett, M. Kirby, S. Ramachandran, 2019, European cardiology.

Controversies in the diagnosis and management of testosterone deficiency syndrome

G. Hackett, 2015, Canadian Medical Association Journal.

A New Perspective on the Nitrate–Phosphodiesterase Type 5 Inhibitor Interaction

R. Kloner, I. Goldstein, I. Osterloh, 2018, Journal of cardiovascular pharmacology and therapeutics.

Sexual health and wellbeing

G. Hackett, 2017 .

Hypogonadism in men with diabetes: Should testosterone replacement therapy be based on evidence based testosterone levels and lifetime risk reduction?

R. Strange, G. Hackett, S. Ramachandran, 2017 .

Clinical and basic science research in sexual medicine must rely, in part, on pharmaceutical funding?

E. Jannini, G. Hackett, M. Sand, 2010, The journal of sexual medicine.